EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor

Nassim Kamar, Dominique Bertrand, Sophie Caillard, Danièle Pievani, Marie Joelle Apithy, Nicolas Congy-Jolivet, Bertrand Chauveau, Fabienne Farce, Arnaud François, Audrey Delas, Jérôme Olagne, Cédric Usureau und 3 weitere

Kidney International Reports · 2024-10 · 9 (10) · 2927-2936

DOI: 10.1016/j.ekir.2024.07.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International Reports, 2024-10. Verfasst von Nassim Kamar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Organ Transplantation, Toulouse University Hospital, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Imlifidase is authorized for desensitization of highly sensitized adult kidney transplant candidates with a positive crossmatch (XM) against a deceased donor. Here, we report on the results for the first 9 patients transplanted in this context who had at least 3 months of follow-up.

Methods

The eligibility criteria were as follows: calculated panel reactive antibodies (cPRA) ³ 98%, ³ 3 years on the waiting list, immunodominant donor-specific antibodies (DSAs) with mean fluorescence intensity (MFI) > 6000 (and < 5000 at 1:10 dilution) and a negative post-imlifidase complement-dependent cytotoxic XM (CDCXM).

Results

All 9 patients had been on dialysis for an average of 123 ± 41 months, with cPRA at 99% (n = 2) or 100% (n = 7). At transplantation, the mean number of DSAs was 4.3 ± 1.4. The median immunodominant DSA MFI was 9153 (6430-16,980). Flow cytometry XM (FCXM) and CDCXM before imlifidase were positive in 9 and 2 patients, respectively. After 1 injection of imlifidase, all were negative. Patients received polyclonal antibodies, i.v. Igs (IVIg), rituximab, tacrolimus, and mycophenolate. Five patients had a DSA rebound within the first 14 days: 2 had concomitant clinical antibody-mediated rejection (ABMR), 2 had subclinical ABMR, and 1 had isolated positive C4d staining. No ABMR was observed in patients without rebound. Chronic Kidney Disease-Epidemiology Collaboration formula estimated glomerular filtration rate (eGFR) was 56 ± 22 ml/min per 1.73 m2 at the last follow-up (7 ± 2.8 months). No graft loss or death were observed. Four patients developed at least 1 infection.

Conclusion

These real-life data demonstrate that the use of imlifidase to desensitize highly sensitized patients can have an acceptable short-term efficacy and safety profile in selected patients.

Schlagwörter

Stichwörter der Autor:innen

highly sensitized patientsimlifidasekidney transplantationpositive crossmatch

Autor:innen und Institutionen

  • Department of Nephrology and Organ Transplantation, Toulouse University Hospital, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Université Paul Sabatier, Toulouse, France.
  • Department of Nephrology, Dialysis and Kidney Transplantation, CHU Rouen, Rouen, France.
  • Department of Nephrology, Dialysis and Transplantation, Strasbourg University Hospital, Strasbourg, France.
  • Department of Nephrology and Renal Transplantation, Saint-Louis Hospital, AP-HP, Université Paris Cité, France CHU Paris-GH Saint-Louis, Paris, France.
  • Laboratoire HLA, Grand Est Blood Center, Strasbourg, France.
  • Laboratoire HLA, Toulouse University Hospital, Toulouse, France.

Zitieren

APA

Kamar, N., Bertrand, D., Caillard, S., Pievani, D., Apithy, M. J., Congy-Jolivet, N., Chauveau, B., Farce, F., François, A., Delas, A., Olagne, J., Usureau, C., Taupin, J. L., Guidicelli, G. L., & Couzi, L. (2024). Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor. Kidney International Reports, 9(10), 2927-2936. https://doi.org/10.1016/j.ekir.2024.07.024

Vancouver

Kamar N, Bertrand D, Caillard S, Pievani D, Apithy MJ, Congy-Jolivet N, et al. Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor. Kidney International Reports. 2024;9(10):2927-2936. doi:10.1016/j.ekir.2024.07.024

BibTeX
@article{Kamar2024,
  author = {Kamar, Nassim and Bertrand, Dominique and Caillard, Sophie and Pievani, Danièle and Apithy, Marie Joelle and Congy-Jolivet, Nicolas and Chauveau, Bertrand and Farce, Fabienne and François, Arnaud and Delas, Audrey and Olagne, Jérôme and Usureau, Cédric and Taupin, Jean-Luc and Guidicelli, Gwenda Line and Couzi, Lionel},
  title = {Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor},
  journal = {Kidney International Reports},
  year = {2024},
  volume = {9},
  number = {10},
  pages = {2927--2936},
  doi = {10.1016/j.ekir.2024.07.024}
}
Kostenlos starten →